Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Minimal gene panel in AML

Lars Bullinger • 15 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia

Lars Bullinger, MD, Charité University of Medicine, Berlin, Germany, discusses the minimal and optimal gene panel in acute myeloid leukemia (AML). The minimal gene panel should include the six gene markers in the current European LeukemiaNet (ELN) guidelines (NPM1, CEBPA, RUNX1, FLT3, TP53, ASXL1) as well as the IDH1 and IDH2 gene mutations. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Lars Bullinger

1:49
Bringing precision medicine and MRD into clinical strategies
Lars Bullinger • 15 Jun 2020
2:09
EHA: AML immuno-oncology updates
Lars Bullinger • 15 Jun 2020
1:36
Innovations in MDS and AML treatment
Lars Bullinger • 15 Jun 2020
1:51
Novel insights into genomic classification and prognosis in AML
Lars Bullinger • 15 Jun 2020

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals